some time back, i fell into a peptide rabbit hole. read everything. started experimenting. couldn't stop.
then India's semaglutide patent expired in march. 25 generics launched overnight. suddenly one of the most powerful drugs in healthcare was accessible - but nobody had built proper infrastructure around it.
no GLP-1 specialists. no monitoring. no cold chain. 1 in 4 indian adults overweight or obese and the system just wasn't ready.
so we built
@ZeltaHealth, doctor-prescribed GLP-1s with full medical oversight, delivery, follow-ups, nutrition, blood work - the whole stack.
5,000 registered patients later, linking up with the head of BD at Novo Nordisk - the company that pioneered GLP-1s with Ozempic and Wegovy.
the peptide space in India is just getting interesting. a lot more to come.